Gilead Sciences, Inc.
NEWS
Days after being tapped to helm the U.S. Centers for Disease Control and Prevention, Dr. Robert Redfield predicted the AIDs epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
The head of GlaxoSmithKline’s pharmaceuticals division is pushing to cut its budget by 20 percent.
Gilead Sciences essentially created a cure for hepatitis C and may be well on its way to developing a cure for HIV-AIDS.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly’s re-submission for their moderate-to-severe rheumatoid arthritis drug.
After serving nearly 30 years with the company Norbert Bischofberger is stepping down from his role as head of research and development and chief scientific officer of Gilead Sciences.
Gilead Sciences announced promising results from a preclinical trial conducted with Beth Israel Deaconess Medical Center as part of an HIV eradication strategy.
Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox.
JOBS
IN THE PRESS